The United States Cutaneous Lymphoma Consortium (USCLC) is a multidisciplinary professional organization dedicated to improve the quality of life and prognosis of patients with cutaneous lymphomas through discovery and application of new knowledge. The need for this organization stems from the fact that the care of patients with cutaneous lymphoma can only be improved by enhanced collaboration and dialogue between health care providers. The USCLC represents the only organization in America where professionals from various disciplines (dermatology, medical oncology, radiation oncology, and pathology) can exchange ideas and practice tips, discuss and plan scientific collaborations, develop new educational tools, and help shape the research agenda in cutaneous lymphoma. The express purpose of the USCLC is to break communication barriers, encourage “outside the box” thinking, and foster and support innovative ideas.

​

The signature initiatives of the USCLC are the USCLC Registry, the Clinical Trials Network (CTN), and the Virtual Tissue Repository (VTR). Through these initiatives, the USCLC is uniquely positioned to transform the field of cutaneous lymphoma by:

​

• Maintaining and updating a searchable and validated database (Registry) of patients with all types of cutaneous lymphoma diagnosed across the United States

• Creating a clinical research infrastructure (CTN) to facilitate prospective clinical trials in cutaneous lymphoma

• Establishing a searchable online archive of tissue from patients with cutaneous lymphoma, obtained and processed through uniform standardized procedures at each participating institution, and linked to clinical data in the Registry.

 

Future initiatives of the USCLC include the development of a biomedical informatics infrastructure to analyze and disseminate digital clinical and pathology images with the purpose to enhance multi-institutional collaborations. Learn more about our mission here.